CN113853369B - [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途 - Google Patents

[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途

Info

Publication number
CN113853369B
CN113853369B CN202080036829.0A CN202080036829A CN113853369B CN 113853369 B CN113853369 B CN 113853369B CN 202080036829 A CN202080036829 A CN 202080036829A CN 113853369 B CN113853369 B CN 113853369B
Authority
CN
China
Prior art keywords
formula
salt
disease
disorder
tartaric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080036829.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113853369A (zh
Inventor
I·雷恩
C·索尼森
R·N·沃特斯
J·M·泰德洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ireland 790 Corp
Original Assignee
Neurosearch AS
Ireland 790 Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS, Ireland 790 Corp filed Critical Neurosearch AS
Publication of CN113853369A publication Critical patent/CN113853369A/zh
Application granted granted Critical
Publication of CN113853369B publication Critical patent/CN113853369B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080036829.0A 2019-05-24 2020-05-20 [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途 Active CN113853369B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19176514 2019-05-24
EP19176514.8 2019-05-24
EP20166361 2020-03-27
EP20166361.4 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (2)

Publication Number Publication Date
CN113853369A CN113853369A (zh) 2021-12-28
CN113853369B true CN113853369B (zh) 2025-08-22

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080036829.0A Active CN113853369B (zh) 2019-05-24 2020-05-20 [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途

Country Status (21)

Country Link
US (2) US12275694B2 (enExample)
EP (2) EP3976581B1 (enExample)
JP (1) JP7623958B2 (enExample)
KR (1) KR102892833B1 (enExample)
CN (1) CN113853369B (enExample)
AU (1) AU2020286003B2 (enExample)
BR (1) BR112021023563A2 (enExample)
CA (1) CA3140805A1 (enExample)
CL (1) CL2021003115A1 (enExample)
CO (1) CO2021016556A2 (enExample)
DK (1) DK3976581T3 (enExample)
ES (2) ES2970361T3 (enExample)
FI (1) FI3976581T3 (enExample)
IL (1) IL288271B2 (enExample)
JO (1) JOP20210312A1 (enExample)
MX (1) MX2021014271A (enExample)
PH (1) PH12021552844A1 (enExample)
PL (1) PL3976581T3 (enExample)
PT (1) PT3976581T (enExample)
SG (1) SG11202112165QA (enExample)
WO (1) WO2020239568A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12275694B2 (en) 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
JP7688690B2 (ja) 2020-07-28 2025-06-04 スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド ピリミジン系化合物の塩、結晶形およびその調製方法
JP2023548429A (ja) * 2020-11-10 2023-11-16 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム）
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions
CA3268423A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts thereof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801924A (zh) * 2007-06-08 2010-08-11 艾尼纳制药公司 (r)-1-{2-[4’-(3-甲氧基-丙烷-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的结晶形式及与其相关的组合物和方法
CN101970408A (zh) * 2007-12-14 2011-02-09 H.隆德贝克有限公司 4-[2，3-二氟-6-(2-氟-4-甲基-苯基硫基)-苯基]-哌啶

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51123821A (en) 1975-04-18 1976-10-28 Nippon Kayaku Co Ltd An algicide and protective agent
US4128574A (en) * 1976-10-04 1978-12-05 General Electric Company Method for making organic polycarboxylic acids
GB8823405D0 (en) 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
ES2169102T3 (es) 1994-10-14 2002-07-01 Merck Patent Gmbh (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano como agente activo sobre el sistema nervioso central.
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
JP2006193494A (ja) 2005-01-17 2006-07-27 Dainippon Ink & Chem Inc ４級アンモニウム系化合物を有効成分とする心臓疾患治療剤
CN101203511A (zh) 2005-06-23 2008-06-18 阿斯利康(瑞典)有限公司 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
WO2007063789A1 (ja) 2005-11-29 2007-06-07 Kissei Pharmaceutical Co., Ltd. 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
WO2007072041A1 (en) 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds
AU2007218086A1 (en) * 2006-02-15 2007-08-30 M's Science Corporation Piperazine derivatives
JP2011519839A (ja) 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
WO2009133110A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
MX2010011724A (es) 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
US9006227B2 (en) * 2011-04-19 2015-04-14 Integrative Research Laboratories Sweden Ab Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
MX391727B (es) 2016-02-08 2025-03-21 Merck Patent Gmbh Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina.
EP3625213B1 (en) 2017-05-19 2023-03-08 Integrative Research Laboratories Sweden AB (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof
SG11202000833YA (en) * 2017-08-07 2020-02-27 Suven Life Sciences Ltd Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
WO2020110128A1 (en) 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US12275694B2 (en) 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801924A (zh) * 2007-06-08 2010-08-11 艾尼纳制药公司 (r)-1-{2-[4’-(3-甲氧基-丙烷-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的结晶形式及与其相关的组合物和方法
CN101970408A (zh) * 2007-12-14 2011-02-09 H.隆德贝克有限公司 4-[2，3-二氟-6-(2-氟-4-甲基-苯基硫基)-苯基]-哌啶

Also Published As

Publication number Publication date
WO2020239568A1 (en) 2020-12-03
JP7623958B2 (ja) 2025-01-29
EP3976581A1 (en) 2022-04-06
MX2021014271A (es) 2022-01-06
KR20220011638A (ko) 2022-01-28
BR112021023563A2 (pt) 2022-01-04
US20240343687A2 (en) 2024-10-17
EP4292653A3 (en) 2024-04-24
US20250243155A1 (en) 2025-07-31
EP4292653A2 (en) 2023-12-20
JOP20210312A1 (ar) 2023-01-30
CO2021016556A2 (es) 2022-01-17
IL288271A (en) 2022-01-01
ES3072819T3 (en) 2026-07-06
PL3976581T3 (pl) 2024-07-01
AU2020286003B2 (en) 2025-04-24
KR102892833B1 (ko) 2025-12-02
CN113853369A (zh) 2021-12-28
EP3976581B1 (en) 2023-11-22
IL288271B2 (en) 2025-02-01
IL288271B1 (en) 2024-10-01
PH12021552844A1 (en) 2022-10-17
EP4292653B1 (en) 2026-03-18
US12275694B2 (en) 2025-04-15
CA3140805A1 (en) 2020-12-03
ES2970361T3 (es) 2024-05-28
DK3976581T3 (da) 2024-01-22
SG11202112165QA (en) 2021-12-30
JP2022533433A (ja) 2022-07-22
PT3976581T (pt) 2024-02-08
US20220267262A1 (en) 2022-08-25
AU2020286003A1 (en) 2021-12-02
CL2021003115A1 (es) 2022-09-30
FI3976581T3 (fi) 2024-01-31

Similar Documents

Publication Publication Date Title
JP7623958B2 (ja) ［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミンの薬学的に許容される塩、およびその使用
US20240148674A1 (en) Pharmaceutically acceptable salts of mesdopetam and uses thereof
US12091384B2 (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
KR20150036081A (ko) 카르바메이트/우레아 유도체
HK40063249A (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
HK40063249B (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
EA047399B1 (ru) Фармацевтически приемлемые соли [2-(3-фтор-5-метансульфонилфенокси)этил](пропил)амина и их применение
CA3064136C (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
JP2026508826A (ja) 抗うつ化合物の塩、その製造方法、それを含む医薬組成物およびその用途
HK40092836A (en) [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias
MX2007009007A (es) Derivados de acido aminobutanoico que inhiben carnitina palmitoil transferasa.
CN121548563A (zh) 3-(2,3-二氟苯氧基)氮杂环丁烷的药学上可接受的盐及其用途
HK40012481B (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
HK40012481A (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063249

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20250604

Address after: Gothenburg

Applicant after: Ireland 790 Corp.

Country or region after: Sweden

Address before: Gothenburg

Applicant before: NEUROSEARCH A/S

Country or region before: Sweden

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant